Skip to main content

Rapastinel FDA Approval Status

FDA Approved: No
Generic name: rapastinel
Previous Name: GLYX-13
Company: Naurex Inc.
Treatment for: Depression

Rapastinel (GLYX-13) is a novel NMDA receptor modulator in clinical development as an intravenous adjunctive therapy for major depressive disorder (MDD).

Development timeline for rapastinel

Mar  3, 2014FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.